MX2018008974A - Nuevos derivados de cianoindolina sustituida como inhibidores de nik. - Google Patents
Nuevos derivados de cianoindolina sustituida como inhibidores de nik.Info
- Publication number
- MX2018008974A MX2018008974A MX2018008974A MX2018008974A MX2018008974A MX 2018008974 A MX2018008974 A MX 2018008974A MX 2018008974 A MX2018008974 A MX 2018008974A MX 2018008974 A MX2018008974 A MX 2018008974A MX 2018008974 A MX2018008974 A MX 2018008974A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- new substituted
- nik
- inhibitors
- nik inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- JXAAHLCOCLPRHW-UHFFFAOYSA-N 2,3-dihydroindole-1-carbonitrile Chemical class C1=CC=C2N(C#N)CCC2=C1 JXAAHLCOCLPRHW-UHFFFAOYSA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 abstract 1
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 abstract 1
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/535—Organo-phosphoranes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152416 | 2016-01-22 | ||
| EP16159651 | 2016-03-10 | ||
| PCT/EP2017/051150 WO2017125530A1 (en) | 2016-01-22 | 2017-01-20 | New substituted cyanoindoline derivatives as nik inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018008974A true MX2018008974A (es) | 2018-11-09 |
Family
ID=57868252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008974A MX2018008974A (es) | 2016-01-22 | 2017-01-20 | Nuevos derivados de cianoindolina sustituida como inhibidores de nik. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11180487B2 (enExample) |
| EP (1) | EP3405196B1 (enExample) |
| JP (1) | JP6910359B2 (enExample) |
| KR (1) | KR102784966B1 (enExample) |
| CN (1) | CN108697710B (enExample) |
| AU (1) | AU2017209935B2 (enExample) |
| BR (1) | BR112018014675B1 (enExample) |
| CA (1) | CA3011880A1 (enExample) |
| DK (1) | DK3405196T3 (enExample) |
| ES (1) | ES2775449T3 (enExample) |
| HR (1) | HRP20200133T1 (enExample) |
| HU (1) | HUE047684T2 (enExample) |
| IL (1) | IL260500B (enExample) |
| LT (1) | LT3405196T (enExample) |
| MX (1) | MX2018008974A (enExample) |
| PH (1) | PH12018501567A1 (enExample) |
| SI (1) | SI3405196T1 (enExample) |
| TW (1) | TWI739783B (enExample) |
| WO (1) | WO2017125530A1 (enExample) |
| ZA (1) | ZA201804688B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3012031C (en) | 2016-01-22 | 2024-03-26 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| JP6740452B2 (ja) * | 2016-07-26 | 2020-08-12 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物 |
| MX2020003240A (es) * | 2017-09-30 | 2020-11-24 | Shanghai Haihe Pharmaceutical Co Ltd | Compuesto que tiene actividad inhibidora de la quinasa erk y su uso. |
| TW202045008A (zh) | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| CN111793031B (zh) * | 2019-04-02 | 2021-06-22 | 海创药业股份有限公司 | 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途 |
| MX2021014679A (es) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb. |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| EP4393508A4 (en) * | 2021-08-23 | 2024-12-04 | Osaka University | COMPOSITION FOR SUPPRESSING TRANSDIFFERENTIATION OF MATURE HEPATOCYTES |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2306671T3 (es) | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
| AU2001237041B9 (en) | 2000-02-17 | 2005-07-28 | Amgen Inc. | Kinase inhibitors |
| CA2401778C (en) | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| CA2441733A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| AU2009263037B2 (en) | 2008-06-26 | 2011-10-06 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| ES2608670T3 (es) | 2009-08-17 | 2017-04-12 | Memorial Sloan-Kettering Cancer Center | Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| PT2598483T (pt) | 2010-07-29 | 2020-10-12 | Rigel Pharmaceuticals Inc | Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos |
| CN103732067A (zh) * | 2011-04-12 | 2014-04-16 | 美国阿尔茨海默病研究所公司 | 化合物，组合物及它们的治疗用途 |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| CA2922657C (en) | 2013-08-30 | 2022-04-12 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| EP3489232A3 (en) | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP2017520526A (ja) | 2014-05-22 | 2017-07-27 | ザ・ユニバーシティ・オブ・シドニー | オメガ−３類似体 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| CN106715419A (zh) | 2014-09-26 | 2017-05-24 | 吉利德科学公司 | 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物 |
| CN106928216A (zh) * | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
| CA3012031C (en) | 2016-01-22 | 2024-03-26 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
-
2017
- 2017-01-20 US US16/071,192 patent/US11180487B2/en active Active
- 2017-01-20 WO PCT/EP2017/051150 patent/WO2017125530A1/en not_active Ceased
- 2017-01-20 CN CN201780007786.1A patent/CN108697710B/zh active Active
- 2017-01-20 CA CA3011880A patent/CA3011880A1/en active Pending
- 2017-01-20 EP EP17701110.3A patent/EP3405196B1/en active Active
- 2017-01-20 HU HUE17701110A patent/HUE047684T2/hu unknown
- 2017-01-20 TW TW105143703A patent/TWI739783B/zh not_active IP Right Cessation
- 2017-01-20 BR BR112018014675-7A patent/BR112018014675B1/pt active IP Right Grant
- 2017-01-20 AU AU2017209935A patent/AU2017209935B2/en active Active
- 2017-01-20 ES ES17701110T patent/ES2775449T3/es active Active
- 2017-01-20 JP JP2018535876A patent/JP6910359B2/ja active Active
- 2017-01-20 KR KR1020187024257A patent/KR102784966B1/ko active Active
- 2017-01-20 SI SI201730183T patent/SI3405196T1/sl unknown
- 2017-01-20 HR HRP20200133TT patent/HRP20200133T1/hr unknown
- 2017-01-20 MX MX2018008974A patent/MX2018008974A/es unknown
- 2017-01-20 DK DK17701110.3T patent/DK3405196T3/da active
- 2017-01-20 LT LTEP17701110.3T patent/LT3405196T/lt unknown
-
2018
- 2018-07-09 IL IL260500A patent/IL260500B/en active IP Right Grant
- 2018-07-13 ZA ZA2018/04688A patent/ZA201804688B/en unknown
- 2018-07-23 PH PH12018501567A patent/PH12018501567A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3011880A1 (en) | 2017-07-27 |
| CN108697710B (zh) | 2022-02-18 |
| ZA201804688B (en) | 2022-03-30 |
| AU2017209935A1 (en) | 2018-08-09 |
| LT3405196T (lt) | 2020-02-25 |
| DK3405196T3 (en) | 2020-03-09 |
| BR112018014675A2 (pt) | 2018-12-11 |
| EP3405196B1 (en) | 2019-12-04 |
| CN108697710A (zh) | 2018-10-23 |
| KR20180100441A (ko) | 2018-09-10 |
| HUE047684T2 (hu) | 2020-05-28 |
| EP3405196A1 (en) | 2018-11-28 |
| ES2775449T3 (es) | 2020-07-27 |
| TW201728577A (zh) | 2017-08-16 |
| US20210087182A1 (en) | 2021-03-25 |
| PH12018501567A1 (en) | 2019-01-28 |
| SI3405196T1 (sl) | 2020-03-31 |
| US11180487B2 (en) | 2021-11-23 |
| JP2019504067A (ja) | 2019-02-14 |
| JP6910359B2 (ja) | 2021-07-28 |
| HRP20200133T1 (hr) | 2020-05-15 |
| IL260500B (en) | 2021-01-31 |
| TWI739783B (zh) | 2021-09-21 |
| AU2017209935B2 (en) | 2021-04-01 |
| BR112018014675B1 (pt) | 2023-12-19 |
| WO2017125530A1 (en) | 2017-07-27 |
| KR102784966B1 (ko) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| MX2017005282A (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
| MX371150B (es) | NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). | |
| EA033237B1 (ru) | Новые производные пиразолопиримидина в качестве ингибиторов nik, фармацевтическая композиция и лекарственное средство, содержащее ее | |
| MX369159B (es) | Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer. | |
| MX2016003863A (es) | Nuevos derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inhibidores de la cinasa inductora de nf-kappab. | |
| MX2017005285A (es) | Nuevos derivados de tienopirimidina en calidad de inhibidores de la cinasa inductora de nf-kb (nik). | |
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| EA201690645A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| MX2020004183A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2019014665A (es) | Nuevos derivados de azaindolina sustituida como inhibidores de nik. | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. | |
| EA201891687A9 (ru) | Новые замещённые производные цианиндолина в качестве nik-ингибиторов | |
| MY192305A (en) | Bipyrazole derivatives as jak inhibitors |